Velarion · Company Intelligence
CompBrief
Fiscal year 2025

Mahkam Zanganeh — FY2025 total compensation $246,047,279

Mahkam Zanganeh is Co-Chief Executive Officer, President and Director of Summit Therapeutics Inc. (SMMT). The company reported total compensation of $246,047,279 for fiscal year 2025.

01

Fiscal year 2025 compensation

Salary$616,500
Bonus$388,395
Stock awards$0
Option awards$245,021,384
Non-equity incentive plan$0
Pension and non-qualified deferred compensation$0
All other compensation$21,000
Total$246,047,279

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed, without adjustment.

Cited to the compensation disclosure Summit Therapeutics Inc. filed April 17, 2026, accession 0001599298-26-000029.

02

History — every fiscal year held

Fiscal yearRoleSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
FY2025Co-Chief Executive Officer, President and Director$616,500$388,395$0$245,021,384$0$0$21,000$246,047,279
FY2024Co-Chief Executive Officer, President and Director$600,000$540,000$0$0$0$0$21,021$1,161,021
FY2023Co-Chief Executive Officer, President and Director$600,000$0$19,905,115$0$0$0$57,809$20,562,924

Totals as disclosed in each year's own compensation disclosure for Summit Therapeutics Inc..

04

The other named executive officers of Summit Therapeutics Inc.

Named executive officerRoleFY2025 total
Manmeet SoniChief Operating Officer, Chief Financial Officer and Director$249,127,782
Mahkam Zanganeh this pageCo-Chief Executive Officer, President and Director$246,047,279
Robert DugganCo-Chief Executive Officer and Chairman of the Board of Directors$172,376

The company's named executive officers for fiscal year 2025, and what it reported for each. See the full Summit Therapeutics Inc. compensation brief.

05

The company page

Mahkam Zanganeh's compensation sits inside Summit Therapeutics Inc.'s full executive and board picture — the peer group, pay against peers, incentive design and the board itself.

The Summit Therapeutics Inc. (SMMT) compensation brief